Correction: Preclinical In Vivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T‑Cell Bispecific in Combination with Anti‑PD‑L1

enthalten in: AAPS PharmSci | 2023

von Sánchez, J. | Nicolini, V. | Fahrni, L. | +9

Correction to: Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology

enthalten in: AAPS PharmSci | 2018

von Pierrillas, P. | Fouliard, S. | Chenel, M. | +3

Performance of Nonlinear Mixed Effects Models in the Presence of Informative Dropout

enthalten in: AAPS PharmSci | 2014

von Björnsson, M. | Friberg, L. | Simonsson, U.

A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer

enthalten in: AAPS PharmSci | 2014

von Bender, B. | Leipold, D. | Xu, K. | +3

Predictions of In Vivo Prolactin Levels from In Vitro Ki Values of $ D_{2} $ Receptor Antagonists Using an Agonist–Antagonist Interaction Model

enthalten in: AAPS PharmSci | 2013

von Petersson, K. | Vermeulen, A. | Friberg, L.